PT-141 (Bremelanotide) Complete Drug-Drug Interaction Profile

How Bremelanotide Works and Why That Matters for Interactions

Bremelanotide is a cyclic heptapeptide that activates melanocortin-4 receptors (MC4R) in the central nervous system, modulating dopaminergic and oxytocinergic pathways involved in sexual arousal 1. Unlike phosphodiesterase-5 inhibitors such as sildenafil, it does not act on vascular smooth muscle directly. Its mechanism is neuroendocrine.

This distinction shapes its interaction profile. Because bremelanotide is a peptide degraded by non-specific tissue peptidases rather than hepatic cytochrome P450 enzymes, it largely avoids the enzyme-inhibition and enzyme-induction interactions that complicate small-molecule drugs 2. The FDA label confirms that bremelanotide is not a substrate, inhibitor, or inducer of major CYP isoforms (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4) 2. It also does not interact with P-glycoprotein or BCRP transporters at clinically relevant concentrations.

Still, the drug produces measurable cardiovascular and gastrointestinal effects that create pharmacodynamic interaction risks, particularly with antihypertensives and opioid-receptor ligands.

The Naltrexone Contraindication

Co-administration with oral naltrexone is the only absolute contraindication listed on the Vyleesi label 2. The concern is not a classic drug-drug interaction in the pharmacokinetic sense. Rather, both drugs can stress hepatic function independently.

Oral naltrexone carries a boxed warning for hepatocellular injury at supratherapeutic doses (300 mg/day), and cases of transaminase elevation have been documented at the standard 50 mg dose used for alcohol-use disorder 3. Bremelanotide, for its part, showed transient transaminase rises in early-phase dose-ranging studies at exposures above the approved 1.75 mg dose 4. The FDA judged the overlap sufficient to warrant contraindication rather than a lesser warning 2.

A practical question arises with low-dose naltrexone (LDN), typically 1.5 to 4.5 mg, which is prescribed off-label for chronic pain and autoimmune conditions. The label does not distinguish between full-dose and low-dose naltrexone. Clinicians should treat the contraindication as applicable to any oral naltrexone formulation until pharmacovigilance data suggest otherwise 5.

Naltrexone administered via extended-release intramuscular injection (Vivitrol) bypasses first-pass hepatic metabolism, but the FDA label still lists "naltrexone" broadly 2. No dedicated interaction study of bremelanotide plus injectable naltrexone has been published. Until such data exist, the safest approach is avoidance.

Antihypertensives and Additive Hypotension

Bremelanotide produces a transient blood-pressure increase of approximately 6/3 mmHg on average, peaking 2 to 3 hours after injection and resolving within 12 hours 2. That sounds paradoxical as an interaction risk with antihypertensives. The concern is actually about the rebound: after the initial pressor effect resolves, patients on background antihypertensive therapy may experience a net drop below their baseline, producing symptomatic hypotension 6.

In the RECONNECT trials (N=1,247), women with controlled hypertension were enrolled, and adverse-event rates for dizziness and nausea were numerically higher in the bremelanotide arm 1. The label advises that bremelanotide "may reduce blood pressure" and recommends monitoring in patients on antihypertensives 2.

Specific antihypertensive classes to monitor include:

Alpha-1 blockers (prazosin, doxazosin, tamsulosin): these already carry orthostatic hypotension risk, and the additive effect with bremelanotide's post-peak pressure dip could be clinically significant, especially within the first 6 hours post-dose 7.

ACE inhibitors and ARBs (lisinopril, losartan): lower baseline risk for orthostasis, but patients titrating to higher doses should be counseled about timing. The FDA label for Vyleesi does not single out specific antihypertensive classes, but the pharmacology of alpha-blockers makes them the highest-risk co-prescription 2.

Diuretics: volume depletion from thiazides or loop diuretics compounds hypotension risk. Patients should maintain adequate hydration on dosing days 8.

Interaction with Oral Contraceptives

A dedicated phase 1 crossover study evaluated bremelanotide 1.75 mg co-administered with a combined oral contraceptive (ethinyl estradiol 30 mcg plus levonorgestrel 150 mcg). Results showed no clinically meaningful change in AUC or Cmax for either ethinyl estradiol or levonorgestrel 2. This is expected, given bremelanotide's lack of CYP3A4 interaction.

The clinical significance for prescribers: contraceptive efficacy is preserved. No dose adjustment or additional barrier method is needed when using bremelanotide alongside hormonal contraceptives 9. This extends logically to progestin-only pills, the etonogestrel implant, and hormonal IUDs, all of which rely on different metabolic pathways from those bremelanotide influences.

Alcohol and Bremelanotide

A formal alcohol interaction study administered bremelanotide 1.75 mg with 0.6 g/kg ethanol (roughly equivalent to two standard drinks for a 70 kg woman). No pharmacokinetic interaction was detected in either direction: bremelanotide did not alter ethanol metabolism, and ethanol did not change bremelanotide exposure 2.

The pharmacodynamic picture is more nuanced. Bremelanotide causes nausea in approximately 40% of patients at first use, and that rate drops to about 22% after the first dose according to pooled RECONNECT data 1. Alcohol itself is emetogenic. The combination does not create a labeled interaction, but the additive nausea burden is worth discussing with patients 10.

Focal hypotension is also a theoretical concern. Ethanol is a vasodilator, and layering it on the post-peak blood-pressure dip from bremelanotide could produce lightheadedness, especially in women who weigh under 60 kg or who are taking concurrent antihypertensives 2.

Interactions with Other Sexual-Health Medications

PDE5 inhibitors (sildenafil, tadalafil): No formal interaction study has been conducted. Bremelanotide acts centrally on MC4R; PDE5 inhibitors act peripherally on vascular smooth muscle. The mechanisms are complementary, and some clinicians have explored off-label combination use for refractory female sexual dysfunction 11. The theoretical risk is additive blood-pressure effects: PDE5 inhibitors lower blood pressure by 8/5 mmHg on average 12, and the bremelanotide post-peak dip could compound that effect. Until dedicated combination data exist, blood-pressure monitoring is prudent.

Flibanserin (Addyi): Both drugs are approved for premenopausal HSDD, but they are not typically combined. Flibanserin acts on serotonin (5-HT1A agonist / 5-HT2A antagonist), while bremelanotide acts on melanocortin receptors. No pharmacokinetic interaction is expected, but flibanserin carries its own hypotension warning, particularly with alcohol 13. Additive blood-pressure lowering would be the concern if both were used in the same 24-hour window.

Testosterone (topical or injectable): Testosterone is sometimes prescribed off-label for female HSDD 14. No pharmacokinetic interaction with bremelanotide is anticipated because testosterone is metabolized by CYP3A4 and UGT enzymes, neither of which bremelanotide affects 2. The combination is unstudied but pharmacologically plausible.

Gastrointestinal Slowing and Co-administered Oral Drugs

Bremelanotide slows gastric emptying. The FDA label notes that Cmax of orally administered drugs may be reduced when taken within 1 hour of a bremelanotide injection 2. This is a class-type effect seen with other melanocortin agonists and with GLP-1 receptor agonists like semaglutide 15.

The practical impact: for drugs with narrow therapeutic indices that rely on rapid absorption for efficacy (e.g., analgesics taken for acute pain, rescue migraine medications like sumatriptan), delayed Tmax could mean delayed onset of action. The total amount absorbed (AUC) is generally unaffected because gastric slowing shifts the absorption curve without reducing bioavailability 2.

Specific guidance: patients who take time-sensitive oral medications should separate dosing by at least 1 hour from the bremelanotide injection. For drugs with narrow therapeutic windows where Cmax matters (certain antibiotics, anticonvulsants), a 2-hour separation is more conservative 16.

Antidepressants and Bremelanotide

SSRIs and SNRIs are the most common medications co-prescribed with bremelanotide in clinical practice because antidepressant-associated sexual dysfunction frequently overlaps with HSDD 17. No formal drug-drug interaction studies have been conducted between bremelanotide and specific SSRIs.

From a pharmacokinetic standpoint, the absence of CYP involvement makes a metabolic interaction unlikely 2. SSRIs like fluoxetine (potent CYP2D6 inhibitor) or fluvoxamine (potent CYP1A2 inhibitor) would not be expected to alter bremelanotide levels.

Pharmacodynamically, both SSRIs and bremelanotide modulate central monoamine signaling. SSRIs increase serotonergic tone, which can suppress sexual desire. Bremelanotide's MC4R activation increases dopaminergic and oxytocinergic signaling 18. These pathways are distinct enough that the combination may be complementary rather than antagonistic. Post-hoc analysis of the RECONNECT data showed that bremelanotide maintained efficacy in patients on background SSRI/SNRI therapy, though sample sizes for this subgroup were limited 1.

Nausea is a shared adverse effect. SSRIs cause nausea in 15 to 25% of patients during initiation 19, and bremelanotide causes nausea in up to 40% at first dose. Patients starting both simultaneously may benefit from staggering initiation or using an antiemetic prophylactically.

Opioids and Melanocortin Signaling

Melanocortin and opioid systems interact bidirectionally in the CNS. Beta-endorphin, the endogenous mu-opioid receptor ligand, is derived from the same POMC precursor peptide that produces alpha-MSH, the endogenous MC4R ligand 20. Exogenous opioids (morphine, oxycodone, hydrocodone) suppress melanocortin signaling, and melanocortin agonists can partially oppose opioid-induced analgesia in animal models 21.

The clinical translation of this preclinical finding is uncertain. No human drug-drug interaction study between bremelanotide and prescription opioids has been published. The FDA label does not list opioids as a contraindication or warning 2. Prescribers should be aware of two theoretical risks: (1) bremelanotide could modestly reduce opioid analgesic efficacy, and (2) opioids could blunt bremelanotide's pro-sexual effects through POMC pathway competition. Neither has been confirmed in controlled human studies.

Summary of Interaction Categories

Contraindicated: Oral naltrexone (any dose).

Use with caution and monitor: Antihypertensives (especially alpha-blockers), PDE5 inhibitors, flibanserin, and alcohol in patients prone to hypotension.

Timing separation recommended: Any oral drug with narrow therapeutic index or time-sensitive absorption. Separate by at least 1 hour.

No clinically significant interaction: Combined oral contraceptives, SSRIs/SNRIs (pharmacokinetic), testosterone, and CYP-metabolized drugs broadly.

Theoretical/unstudied: Opioids, injectable naltrexone, GLP-1 receptor agonists (additive gastroparesis), and dopamine agonists.

Patients initiating bremelanotide should bring a complete medication list, including OTC drugs and supplements, to their prescriber. The 1.75 mg dose should not be exceeded, and the 8-dose-per-month ceiling should be observed regardless of co-medications 2.